A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 8, 2021

Study Completion Date

February 24, 2025

Conditions
Cervical Cancer
Interventions
DRUG

Tiragolumab

Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

DRUG

Atezolizumab

Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Trial Locations (56)

110

National Taiwan University Hospital, Taipei

333

Chang Gung Medical Foundation, Linkou Branch, Taoyuan

4101

Mater Misericordiae Limited, South Brisbane

10103

Clinica CIMCA, San José

10108

ICIMED Instituto de Investigación en Ciencias Médicas, San José

11217

Taipei Veterans General Hospital, Taipei

13009

Institut Paoli Calmettes, Marseille

15006

Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña

20141

Istituto Europeo Di Oncologia, Milan

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

30912

Augusta University, Augusta

34298

Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier

40705

Taichung Veterans General Hospital, Taichung

41931

Keimyung University Dongsan Hospital, Daegu

44805

ICO - Site René Gauducheau, Saint-Herblain

50200

Maharaj Nakorn Chiang Mai Hospital, Muang

64570

Christus Muguerza Clinica Vidriera, Monterrey

69008

Centre Leon Berard, Lyon

80131

Istituto Tumori Napoli, Napoli

85016

Arizona Oncology Associates, Phoenix

92616

Kaiser Permanente - Irvine, Irvine

94800

Gustave Roussy, Villejuif

97401

Oncology Associates of Oregon, P.C, Eugene

143422

MEDSI Clinical Hospital on Pyatnitsky Highway, Moscow

400138

Volgograd Regional Clinical Oncology Dispensary, Volgograd

420029

Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan'

454087

Chelyabisnk regional clinical center for oncology and nuclear medicine, Chelyabinsk

634050

Tomsk scientific research institute of oncology SO RAMN, PAD, Tomsk

41253-190

Hospital Sao Rafael - HSR, Salvador

74605-070

Hospital Araujo Jorge, Goiânia

98700-000

Hospital de Caridade de Ijui, Ijuí

91350-200

Hospital Nossa Senhora da Conceicao, Porto Alegre

01317-000

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, São Paulo

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

N6A 4L6

London Regional Cancer Centre, London

M5G 1Z5

Princess Margaret Cancer Center, Toronto

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University Health Centre - Glen Site, Montreal

00168

Policlinico Universitario Agostino Gemelli, Rome

0801

Centro Oncológico de Panamá, Panama City

0832

The Panama Clinic, Panama City

Lima 27

Clinica Ricardo Palma, San Isidro

81-519

Szpital Morski im.PCK, Gdynia

44-101

Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice, Gliwice

61-866

Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie, Poznan

02-781

Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie, Warsaw

01812

Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

Unknown

Mackay Memorial Hospital, Taipei

NW1 - 2PG

University College London Hospital, London

W1G 6AD

Sarah Cannon Research Institute, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04300647 - A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer | Biotech Hunter | Biotech Hunter